Cargando…

Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity

Tripterygium glycosides tablets (TGT) are widely used for treating nephrotic syndrome (NS), but hepatotoxicity is frequently reported. The presence of underlying disease(s) can alter the disposition of drugs and affect their efficacy and toxicity. However, no studies have reported the impact of NS o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wei, Cheng, Rui, Boucetta, Hamza, Xu, Lei, Pan, Jing–ru, Song, Min, Lu, Yu–ting, Hang, Tai–jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221999/
https://www.ncbi.nlm.nih.gov/pubmed/35754482
http://dx.doi.org/10.3389/fphar.2022.910923
_version_ 1784732765143433216
author Wu, Wei
Cheng, Rui
Boucetta, Hamza
Xu, Lei
Pan, Jing–ru
Song, Min
Lu, Yu–ting
Hang, Tai–jun
author_facet Wu, Wei
Cheng, Rui
Boucetta, Hamza
Xu, Lei
Pan, Jing–ru
Song, Min
Lu, Yu–ting
Hang, Tai–jun
author_sort Wu, Wei
collection PubMed
description Tripterygium glycosides tablets (TGT) are widely used for treating nephrotic syndrome (NS), but hepatotoxicity is frequently reported. The presence of underlying disease(s) can alter the disposition of drugs and affect their efficacy and toxicity. However, no studies have reported the impact of NS on the ADME profiles of TGT or its subsequent impact on the efficacy and toxicity. Thus, the efficacy and hepatotoxicity of TGT were evaluated in normal and NS rats after oral administration of TGT (10 mg/kg/day) for 4 weeks. The corresponding ADME profiles of the six key TGT components (triptolide (TPL), wilforlide A (WA), wilforgine (WFG), wilfortrine (WFT), wilfordine (WFD), and wilforine (WFR)) were also measured and compared in normal and NS rats after a single oral gavage of 10 mg/kg TGT. Canonical correlation analysis (CCA) of the severity of NS and the in vivo exposure of the six key TGT components was performed to screen the anti–NS and hepatotoxic material bases of TGT. Finally, the efficacy and hepatotoxicity of the target compounds were evaluated in vitro. The results showed that TGT decreased the NS symptoms in rats, but caused worse hepatotoxicity under the NS state. Significant differences in the ADME profiles of the six key TGT components between the normal and NS rats were as follows: higher plasma and tissue exposure, lower urinary and biliary excretion, and higher fecal excretion for NS rats. Based on CCA and in vitro verification, TPL, WA, WFG, WFT, WFD, and WFR were identified as the anti–NS material bases of TGT, whereas TPL, WFG, WFT, and WFD were recognized as the hepatotoxic material bases. In conclusion, NS significantly altered the ADME profiles of the six key TGT components detected in rats, which were related to the anti–NS and hepatotoxic effects of TGT. These results are useful for the rational clinical applications of TGT.
format Online
Article
Text
id pubmed-9221999
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92219992022-06-24 Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity Wu, Wei Cheng, Rui Boucetta, Hamza Xu, Lei Pan, Jing–ru Song, Min Lu, Yu–ting Hang, Tai–jun Front Pharmacol Pharmacology Tripterygium glycosides tablets (TGT) are widely used for treating nephrotic syndrome (NS), but hepatotoxicity is frequently reported. The presence of underlying disease(s) can alter the disposition of drugs and affect their efficacy and toxicity. However, no studies have reported the impact of NS on the ADME profiles of TGT or its subsequent impact on the efficacy and toxicity. Thus, the efficacy and hepatotoxicity of TGT were evaluated in normal and NS rats after oral administration of TGT (10 mg/kg/day) for 4 weeks. The corresponding ADME profiles of the six key TGT components (triptolide (TPL), wilforlide A (WA), wilforgine (WFG), wilfortrine (WFT), wilfordine (WFD), and wilforine (WFR)) were also measured and compared in normal and NS rats after a single oral gavage of 10 mg/kg TGT. Canonical correlation analysis (CCA) of the severity of NS and the in vivo exposure of the six key TGT components was performed to screen the anti–NS and hepatotoxic material bases of TGT. Finally, the efficacy and hepatotoxicity of the target compounds were evaluated in vitro. The results showed that TGT decreased the NS symptoms in rats, but caused worse hepatotoxicity under the NS state. Significant differences in the ADME profiles of the six key TGT components between the normal and NS rats were as follows: higher plasma and tissue exposure, lower urinary and biliary excretion, and higher fecal excretion for NS rats. Based on CCA and in vitro verification, TPL, WA, WFG, WFT, WFD, and WFR were identified as the anti–NS material bases of TGT, whereas TPL, WFG, WFT, and WFD were recognized as the hepatotoxic material bases. In conclusion, NS significantly altered the ADME profiles of the six key TGT components detected in rats, which were related to the anti–NS and hepatotoxic effects of TGT. These results are useful for the rational clinical applications of TGT. Frontiers Media S.A. 2022-06-09 /pmc/articles/PMC9221999/ /pubmed/35754482 http://dx.doi.org/10.3389/fphar.2022.910923 Text en Copyright © 2022 Wu, Cheng, Boucetta, Xu, Pan, Song, Lu and Hang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wu, Wei
Cheng, Rui
Boucetta, Hamza
Xu, Lei
Pan, Jing–ru
Song, Min
Lu, Yu–ting
Hang, Tai–jun
Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title_full Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title_fullStr Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title_full_unstemmed Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title_short Differences in Multicomponent Pharmacokinetics, Tissue Distribution, and Excretion of Tripterygium Glycosides Tablets in Normal and Adriamycin–Induced Nephrotic Syndrome Rat Models and Correlations With Efficacy and Hepatotoxicity
title_sort differences in multicomponent pharmacokinetics, tissue distribution, and excretion of tripterygium glycosides tablets in normal and adriamycin–induced nephrotic syndrome rat models and correlations with efficacy and hepatotoxicity
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221999/
https://www.ncbi.nlm.nih.gov/pubmed/35754482
http://dx.doi.org/10.3389/fphar.2022.910923
work_keys_str_mv AT wuwei differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT chengrui differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT boucettahamza differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT xulei differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT panjingru differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT songmin differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT luyuting differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity
AT hangtaijun differencesinmulticomponentpharmacokineticstissuedistributionandexcretionoftripterygiumglycosidestabletsinnormalandadriamycininducednephroticsyndromeratmodelsandcorrelationswithefficacyandhepatotoxicity